Core Viewpoint - The legal opinion letter confirms that Shenzhen Xinxing Light Alloy Materials Co., Ltd. has obtained the necessary approvals and authorizations for its 2025 stock option incentive plan, which aims to grant stock options to eligible employees under specified conditions [1][4][9]. Group 1: Legal Framework and Approval - The legal opinion is issued by Guangdong Prometheus (Longgang) Law Firm, confirming compliance with relevant laws and regulations, including the Company Law and Securities Law [2][3]. - The company has received approval from the board of directors and the supervisory board for the stock option incentive plan, ensuring that all necessary procedures have been followed [4][6]. Group 2: Granting Conditions and Specifics - The stock option incentive plan specifies that stock options can only be granted if certain conditions are met, including the absence of negative audit opinions in the most recent financial reports [6][8]. - The stock options have a maximum validity period of 36 months from the date of grant, with a waiting period of 12 to 24 months before they can be exercised [7][9]. Group 3: Performance Assessment and Targets - The performance assessment for the stock options is based on the company's revenue growth compared to the 2024 fiscal year, with specific growth targets set for the years 2025 and 2026 [9]. - The plan outlines that if performance targets are not met, the stock options will be canceled, and the individual performance assessments will also affect the ability to exercise options [9][10].

Core Viewpoint - Shenzhen New Star Light Alloy Materials Co., Ltd. has initiated a stock option incentive plan for 2025, which aims to motivate and retain key personnel by granting stock options under specific conditions [1][2][3]. Summary by Sections 1. Definition and Context - The report defines key terms related to the stock option incentive plan, including "incentive objects," "exercise price," and "waiting period" [1][2]. 2. Approval Process - The stock option incentive plan has undergone necessary approval procedures, including meetings of the board of directors and the supervisory board, which reviewed and approved the plan [4][5][6]. 3. Granting Details - The first grant date is set for July 16, 2025, with a total of 2 million stock options awarded to 6 individuals, including directors and senior management [7][8]. - The exercise price is established at 13.33 RMB per share [8]. 4. Conditions for Granting - The granting of stock options is contingent upon the company and the incentive objects meeting specific conditions, ensuring compliance with relevant laws and regulations [9][10]. 5. Financial Impact - The implementation of the stock option incentive plan is expected to be accounted for in accordance with accounting standards, with potential dilution effects noted for shareholders [9][10].

Core Viewpoint - The legal opinion letter from Grandall Law Firm (Shenzhen) confirms that the adjustment of the exercise price for the 2021 stock option incentive plan of Te Yi Pharmaceutical Group Co., Ltd. has obtained the necessary approvals and complies with relevant regulations [1][4][5]. Group 1: Approval and Authorization - The board of directors has authorized the adjustment of the exercise price for the stock option incentive plan, which is now set at 6.19 yuan per share [4][5]. - The adjustment is deemed to be in accordance with the provisions of the stock incentive plan and relevant regulations [4][5]. Group 2: Specifics of the Adjustment - The adjustment was necessitated by a cash dividend distribution of 0.50 yuan per 10 shares, with no stock dividends or capital increases [4][5]. - The formula used for the adjustment of the exercise price is P = P0 - V, where P0 is the original exercise price, V is the cash dividend per share, and P is the adjusted exercise price [5]. - Following the adjustment, the exercise price changed from 6.24 yuan per share to 6.19 yuan per share [5]. Group 3: Conclusion - The legal opinion concludes that the adjustment has received the necessary approvals and is in compliance with the relevant laws and regulations [5][6]. - The company is required to fulfill its information disclosure obligations and complete the necessary procedures related to this adjustment [5].

Group 1 - The legal opinion letter is issued regarding the adjustment of the exercise price for the 2025 stock option incentive plan of Xiamen Yingqu Technology Co., Ltd. [1][3] - The adjustment of the exercise price has been approved and authorized by the board of directors, supervisory board, and shareholders' meeting, complying with relevant laws and regulations [4][5] - The adjustment is based on the company's cash dividend distribution plan, which involves distributing a cash dividend of 3.00 yuan per 10 shares, leading to a reduction in the exercise price [4][5] Group 2 - The adjustment method for the exercise price follows the stipulated formula, where the new exercise price is calculated by subtracting the cash dividend per share from the previous exercise price [5] - The adjusted exercise price is determined to be 13.70 yuan minus 0.30 yuan, resulting in a new exercise price of 13.40 yuan per share [5] - The legal opinion concludes that the adjustment method and results are in accordance with the relevant regulations and the incentive plan draft [5]

Core Viewpoint - The company has adjusted the exercise price of the 2025 stock option incentive plan from 13.70 yuan to 13.40 yuan per share due to a cash dividend distribution [1][5][6] Group 1: Approval Process and Disclosure - The company held multiple meetings to approve the stock option incentive plan, including the board and supervisory committee meetings on March 7, March 12, and March 27, 2025 [2][3][4] - The plan was publicly disclosed and no objections were raised during the internal announcement period [2][3] - The first grant of stock options was completed on May 16, 2025, following the necessary approvals [4] Group 2: Adjustment Explanation - The adjustment of the exercise price is based on the company's cash dividend distribution of 3.00 yuan per 10 shares, which led to a decrease in the exercise price by 0.30 yuan [5] - The new exercise price of 13.40 yuan is calculated as 13.70 yuan minus the dividend amount [5] Group 3: Impact of Adjustment - The adjustment of the exercise price will not have a significant impact on the company's financial condition or operating results [5][6] - The supervisory committee and legal advisors have confirmed that the adjustment complies with relevant regulations and has received the necessary approvals [6]

Core Viewpoint - The announcement details the third exercise period of the stock option incentive plan for Zhejiang Shuanghuan Transmission Machinery Co., Ltd, highlighting the conditions for exercising options and the adjustments made to the plan [1][2][3]. Summary by Sections Stock Option Exercise Details - The third exercise period allows 370 incentive participants to exercise stock options from July 21, 2025, to May 22, 2026 [1]. - The total number of stock options available for exercise during this period is 672,300 shares, with a corresponding exercise ratio of approximately 30% [19]. Approval and Compliance - The self-exercise conditions have been approved by the Shenzhen Stock Exchange, and the company has completed the necessary registration with the China Securities Depository and Clearing Corporation [2]. - The company has followed all required approval procedures for the 2022 stock option incentive plan, including the review of related proposals by the board and supervisory committee [3][4]. Performance Assessment - The performance assessment for the third exercise period is based on the company's net profit target of no less than 950 million yuan for the year 2024, with the actual profit reported at approximately 1.038 billion yuan, resulting in a performance achievement rate of 109.26% [9][10]. - Out of the incentive participants, 368 achieved "excellent" or "good" performance ratings, allowing them to exercise their options at a 100% rate [10]. Adjustments and Cancellations - The stock option plan has undergone adjustments, including changes in the number of participants and the exercise price due to equity distributions, with the exercise price adjusted from 16.69 yuan to 16.57 yuan [6][12][15]. - A total of 218,040 stock options have been canceled due to participants leaving the company or not meeting performance conditions [18]. Impact on Company Structure - If all options are exercised, the company's total share capital will increase by 2,016,300 shares, with the new share structure remaining compliant with listing requirements [20][21]. - The exercise of options is not expected to significantly impact the company's earnings per share or return on equity [21].

Core Viewpoint - The company conducted a self-examination regarding the trading activities of insiders and incentive recipients related to the 2025 stock option incentive plan, confirming no insider trading occurred during the specified period [1][2][3]. Group 1: Self-Examination Process - The company implemented necessary confidentiality measures and registered insiders involved in the 2025 stock option incentive plan [2]. - A self-examination was conducted for the period from December 9, 2024, to June 9, 2025, focusing on the trading activities of insiders and incentive recipients [2][3]. Group 2: Findings on Insider Trading - Four insiders were found to have traded company stock during the self-examination period, but their transactions occurred before being classified as insiders, indicating no misuse of insider information [3]. - A total of 48 incentive recipients also engaged in stock trading, and their actions were based on independent market judgments without knowledge of the incentive plan details [3]. Group 3: Compliance and Conclusion - The company adhered to relevant laws and regulations, ensuring that only a limited number of personnel had access to insider information during the planning of the incentive program [3]. - The examination concluded that there were no instances of insider trading or information leakage related to the incentive plan, aligning with legal requirements [3].

博济医药科技股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 二、 监事会会议审议情况 经审核，监事会一致认为：公司本次调整股票期权激励计划行权价格事项符 合公司《2022 年股票期权激励计划（草案）》《2022 年股票期权激励计划实施考 核管理办法》等有关规定，不存在损害公司及全体股东利益的情形。因此，公司 监事会同意本次调整股票期权激励计划行权价格事项。 表决结果：同意 3 票；反对 0 票；弃权 0 票。 价格的议案》 证券代码：300404 证券简称：博济医药 公告编号：2025-057 记载、误导性陈述或重大遗漏。 一、 监事会会议召开情况 博济医药科技股份有限公司（以下简称"公司"）第五届监事会第十四次会 议于 2025 年 7 月 15 日在公司会议室召开，会议采取现场投票方式对议案进行表 决。本次会议通知于 2025 年 7 月 11 日以专人送达、电子邮件、电话、微信等方 式发出。会议应到监事 3 人，实到 3 人。会议由监事会主席刘菁纯女士主持。本 次监事会的召集、召开符合《公司法》《公司章程》及相关法规的规定。 表决结果：同意 3 票；反对 0 票；弃权 ...

Group 1 - The 16th meeting of the 11th Supervisory Board was held on July 15, 2025, via communication method, and the resolutions passed are deemed legal and effective according to the Company Law and Articles of Association [1] - The Supervisory Board approved the proposal to adjust the exercise price of the 2020 stock option incentive plan, confirming that the adjustment complies with relevant laws and regulations, and does not harm the interests of the company and its shareholders [1] - The voting results for the proposal were 3 votes in favor, 0 votes against, and 0 abstentions, indicating unanimous support for the adjustment [1] Group 2 - The company is associated with various bond codes, including 127108 (Tai Neng Convertible Bond), 149812 (22 Solar G1), and 148296 (23 Solar GK02) [2]

Core Viewpoint - The company has adjusted the exercise price of its 2020 stock option incentive plan from 4.196 yuan per share to 4.140 yuan per share due to the implementation of profit distribution [1][10][12]. Group 1: Adjustment Details - The adjustment of the stock option exercise price is a result of the company's profit distribution plan, which was approved at the annual general meeting held on May 15, 2025, and implemented on July 11, 2025 [10][12]. - The profit distribution plan involves a cash dividend of 0.559889 yuan per 10 shares, with no bonus shares or capital reserve transfers [10][12]. - The formula used for the adjustment is P = P0 - V, where P0 is the original exercise price, and V is the dividend per share [12]. Group 2: Compliance and Approval - The adjustment complies with relevant regulations, including the "Management Measures for Equity Incentives of Listed Companies" and the company's own incentive plan [12]. - The supervisory board has reviewed the adjustment and confirmed that it does not harm the interests of the company or its shareholders [12]. - Legal opinions confirm that the adjustment has received necessary approvals and complies with applicable laws and regulations [12].